Peter Reiss


Peter Reiss

  • Senior Fellow
  • Professor of Medicine, Department of Global Health, Amsterdam UMC, University of Amsterdam
  • Academic Staff
  • Director Stichting HIV Monitoring

Prof. Peter Reiss has been involved in HIV care and research since the start of the pandemic in 1981. Although his research currently largely focuses on the long-term complications of HIV and HIV treatment, and more particularly in relation to ageing (see ), he also participates in research concerning HIV cure, and research aimed towards zero new HIV infections in Amsterdam. Ultimately, his career has centred around improving understanding and management of the complications of HIV infection and the treatment of this infection.


He is currently Professor of Medicine (emeritus) at the Department of Global Health, Amsterdam UMC, University of Amsterdam, the Netherlands, and maintains an appointment as senior fellow at the Amsterdam Institute for Global Health and Development. He is a member of the Scientific Advisory Board of the Pierre Louis Institute of Epidemiology and Public Health in Paris, France, the US NIH/NIAID HIV Vaccine Data and Safety Monitoring Board, and programme committee member of  CROI, the EACS Conference and HIV Glasgow. Professor Reiss is clinical HIV section editor for Antiviral Therapy. He currently (co-) supervises PhD students both in Amsterdam as well as in Thailand and Tanzania.


Professor Reiss served as the Director of the Netherlands HIV Monitoring Foundation until April 2021. He served as EACS President (2008-2012), on the Governing Council of IAS (2006 – 2014), and as co-chair of the 22nd International AIDS Conference (AIDS 2018).

View Peter’s publications (PubMed) 


Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study.
Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P; AGEhIV Cohort Study Group..Clin Infect Dis. 2014 Dec 15;59(12):1787-97. doi: 10.1093/cid/ciu701. Epub 2014 Sep 2.PMID:25182245

Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease.
Kooij KW, Wit FW, Bisschop PH, Schouten J, Stolte IG, Prins M, van der Valk M, Prins JM, van Eck-Smit BL, Lips P, Reiss P; AGEhIV Cohort Study group..J Infect Dis. 2015 Feb 15;211(4):539-48. doi: 10.1093/infdis/jiu499. Epub 2014 Sep 1.PMID:25180239

Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure.
van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA, Wiersinga WJ, Prins M, van den Born BJ, Reiss P; AGEhIV Cohort Study Group..Clin Infect Dis. 2016 Jul 15;63(2):205-13. doi: 10.1093/cid/ciw285. Epub 2016 May 3.PMID:27143668

Increased brain-predicted aging in treated HIV disease.
Cole JH, Underwood J, Caan MW, De Francesco D, van Zoest RA, Leech R, Wit FW, Portegies P, Geurtsen GJ, Schmand BA, Schim van der Loeff MF, Franceschi C, Sabin CA, Majoie CB, Winston A, Reiss P, Sharp DJ; COBRA collaboration..Neurology. 2017 Apr 4;88(14):1349-1357. doi: 10.1212/WNL.0000000000003790. Epub 2017 Mar 3.PMID:28258081

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid.
Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Garagnani P, Pirazzini C, Franceschi C, Fuchs D, Gisslén M, Winston A, Reiss P, Kootstra NA; Comorbidity in Relation to AIDS (COBRA) Collaboration .
Open Forum Infect Dis. 2017 May 25;4(3):ofx108. doi: 10.1093/ofid/ofx108. eCollection 2017 Summer. PMID: 28680905